Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Orilyse
- Development stage
- Unknown
- Lead developer
- IBSA
- Modality
- Small Molecules
- Administration
- Otic
01
Overview
Orilyse is an otic solution developed by Laboratoires Genévrier (IBSA Pharma) for the removal of cerumen (earwax) and epidermal blockages in the ear canal. Formulated as ear drops, it contains 95% sweet almond oil, which acts as an emollient to soften and hydrate the earwax, and 5% xylene, which serves as a solvent to dissolve the blockage. This dual-action medical device facilitates the natural elimination of earwax plugs, helping to relieve associated symptoms such as hearing loss, tinnitus, and dizziness.
- Brand names
- Orilyse
- Other names
- Orilyse Gouttes Auriculairesxylene + sweet almond oil
Beyond the preview
Go deeper on Orilyse.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Orilyse.